🔗 Share this article

As the US proceeds with historic changes to its immunization recommendations, an unexpected name has surfaced somewhat surprisingly: Høeg, a Danish American sports physician and public health researcher who first made her name by questioning COVID-19 vaccinations in the global health crisis and has concentrated on alleged fatalities following Covid vaccination in her recent tenure at the US Food and Drug Administration (FDA).

Scheduled Changes to Childhood Vaccine Schedule

Health officials planned to announce radical revisions to the childhood immunization program recently, bringing the US with the Danish immunization schedule, sources say – a significant shift that would place the US at odds with much of the global community with little proof for improved outcomes. The planned update has been postponed until the coming year.

In place of Vinay Prasad, Høeg is listed to speak at the gathering. She was newly appointed acting director of the FDA’s drug evaluation center, the fifth individual to head the office this calendar year.

A New Direction at the Regulatory Body

The acting appointment might represent a closer partnership between the pharmaceutical and vaccine centers as Dr. Høeg and Dr. Prasad consolidate power at the regulatory agency – and it signals a renewed priority upon reevaluating previously authorized vaccines at the FDA.

Dr. Høeg has often pushed for halting certain childhood shot schedules in the US in order to be more like Denmark, a nation with universal health coverage and a number of inhabitants roughly the population of Wisconsin’s.

In her initial comments, she has continued to focus on vaccination policy – typically the responsibility of Prasad, head of the FDA’s vaccine center – instead of drug regulation.

Questions Over Expertise

Høeg has no obvious experience in pharmaceutical research, oversight or leadership, which has been standard for former directors of the biologics center. She has been employed at the FDA as a top consultant to the agency head and the vaccine center since earlier this year.

“It seems she lacks to have any of the qualifications” for leading the pharmaceutical oversight division, said Dr. Jonathan Howard. “She’s never run a clinical trial. She is not versed in managing a major agency. She is not an expert in industry regulation.”

Former heads of CBER would “understand regulatory frameworks and the science of pharmaceutical innovation”, noted a former acting FDA commissioner. “Clearly, she has not acquired the sort of resume that former directors who led the center have had.”

The drug center has an enormous portfolio at the agency, the former commissioner pointed out.

“Many people just zeroes in on the new drug program, but the generic drug division authorizes thousands of off-brand pharmaceuticals. There’s a biosimilars program, OTC medication office and so forth, and all of those need to be supervised,” she noted. “The responsibility you neglect, that is the part that I always told people is going to bite you.”

Additionally, a significant administrative component to the job, which manages more than 5,000 employees. “It is a enormous management job, if you execute it properly,” she said.

Agency Reaction and Contentious Initiatives

In response to questions about Høeg’s qualifications and whether this assignment represents greater collaboration among regulatory chiefs on vaccines, a press secretary said that the “inquiries are based on flawed presumptions”.

“This background aligns with the duties of her role,” the representative explained, citing the time Høeg spent counseling the agency head on “pharmaceutical safety and regulatory science, including computational safety modeling and immunization monitoring”.

In her interim role, Høeg inherits the commissioner’s new priority voucher program, a disputed expedited medication authorization process that reportedly worried her preceding directors. “By what process are these medications being picked for this expedited pathway? Who makes the decisions?” Dr. Howard said. “There is a lot of lack of transparency occurring at the agency right now.”

Overall, he stated, “the Food and Drug Administration seems to be moving towards laxer oversight of most medications, except for vaccines.”

Documented Track Record on Vaccines

Concerning vaccines, Dr. Høeg has a more documented, if problematic, history, Howard observe. She authored a analysis using non-validated volunteer-provided data to estimate the frequency of heart inflammation after COVID-19 vaccination. She consulted for the Florida top health official Joseph Ladapo, who was said to have changed statistics to indicate COVID-19 vaccines are riskier than they are.

Part of her “wish list” for the new federal leadership featured changing rules for novel immunizations and ending “unnecessary” vaccines, she remarked following the vote on a audio program. At the agency, Høeg has according to sources floated the idea of barring teenage boys from getting Covid vaccines.

“She’s an complete true believer who begins with her beliefs and reverse-engineers to accommodate the science in a extremely disingenuous, dishonest fashion,” Dr. Howard stated.

Taking Control and a “Revenge Tour”

Høeg joined fellow dissenters, {like|